Bliss GVS Pharma Ltd Stock Price Today (NSE: BLISSGVS)
Fundamental Score
Bliss GVS Pharma Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Bliss GVS Pharma Ltd share price today is ₹465.65, up +2.31% on NSE/BSE as of 31 July 2026. Bliss GVS Pharma Ltd (BLISSGVS) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹5.44K (Cr). The 52-week high for BLISSGVS share price is ₹553.00 and the 52-week low is ₹118.00. At a P/E ratio of 41.25x, BLISSGVS is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 11.75% and a debt-to-equity ratio of 0.02.
Bliss GVS Pharma Ltd Share Price Chart — NSE/BSE Historical Performance
Bliss GVS Pharma Ltd share price chart: -11.06% return over the past month. 52-week high ₹553.00, 52-week low ₹118.00.
Bliss GVS Pharma Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹455.50 | ₹474.00 | ₹455.15 | ₹465.65 | 2.90L (Cr) | |
| ₹460.00 | ₹464.85 | ₹452.50 | ₹455.15 | 2.39L (Cr) | |
| ₹443.00 | ₹469.95 | ₹443.00 | ₹456.00 | 1.74L (Cr) | |
| ₹457.00 | ₹462.80 | ₹448.45 | ₹450.10 | 3.30L (Cr) | |
| ₹461.30 | ₹463.95 | ₹451.00 | ₹459.40 | 2.24L (Cr) | |
| ₹450.00 | ₹468.00 | ₹450.00 | ₹464.60 | 1.25L (Cr) | |
| ₹450.00 | ₹470.50 | ₹450.00 | ₹461.85 | 2.22L (Cr) | |
| ₹473.05 | ₹489.00 | ₹466.75 | ₹467.60 | 1.45L (Cr) | |
| ₹496.00 | ₹500.25 | ₹466.10 | ₹482.70 | 3.89L (Cr) | |
| ₹505.20 | ₹510.00 | ₹479.75 | ₹483.50 | 3.67L (Cr) |
Bliss GVS Pharma Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹538.95 | ₹547.40 | ₹443.00 | ₹465.65 | -13.60% | |
| ₹423.95 | ₹553.00 | ₹397.00 | ₹539.60 | +27.28% | |
| ₹278.80 | ₹438.00 | ₹265.00 | ₹425.30 | +52.55% | |
| ₹228.00 | ₹281.00 | ₹220.30 | ₹276.76 | +21.39% | |
| ₹204.00 | ₹230.98 | ₹193.07 | ₹215.59 | +5.68% | |
| ₹168.70 | ₹243.37 | ₹166.36 | ₹212.05 | +25.70% | |
| ₹164.90 | ₹195.80 | ₹152.26 | ₹176.73 | +7.17% | |
| ₹167.31 | ₹183.78 | ₹140.80 | ₹163.39 | -2.34% | |
| ₹156.09 | ₹177.94 | ₹118.00 | ₹165.98 | +6.34% | |
| ₹152.79 | ₹165.00 | ₹149.50 | ₹156.86 | +2.66% | |
| ₹156.49 | ₹167.75 | ₹143.00 | ₹152.46 | -2.58% | |
| ₹175.20 | ₹187.94 | ₹155.01 | ₹155.70 | -11.13% |
AI Research Briefing
Powered by Gemini · 2026-04-09
Small-cap pharma play riding export tailwinds, but Q3 profit decline and high debtor days warrant caution.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Bliss GVS Pharma reached a new all-time high of on April 7, 2026. The company also appointed two independent directors for five-year terms. The trading window for insiders closed on April 1, 2026, ahead of the FY26 results.
CORE STORY (THE REAL GAME)
Bliss GVS is being priced as a beneficiary of the broader India Pharma growth story, specifically its export capabilities and formulations. The market is betting on continued growth in key therapeutic segments like suppositories and pessaries, where they have a global presence.
- Technical breakout to all-time high
- India pharma export growth of 5.6%
- Appointment of independent directors
- Strong FY26 earnings beat
- New order wins in key export markets
- Successful backward integration into APIs
- Micro-cap liquidity risk
- Q3 FY26 profit decline
- High debtor days (198)
FII increased holdings by 0.62%, while DII decreased holdings by 0.56%. Promoter holding remains stable with a slight decrease of 0.05%.
Indian pharmaceutical industry projected to reach $130 billion by 2030, driven by expanding global demand.
Free Cash Flow 5Y: ₹167.14 Cr
Expect continued growth in exports and formulations over the next 3-6 months. Monitor Q4 results closely for confirmation of earnings recovery and working capital improvement.
Primary Thesis Risk
Earnings volatility and working capital issues could derail the export growth story.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Bliss GVS Pharma Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Bliss GVS Pharma Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of BLISSGVS across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Excellent ROCE Performance (16.93%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (17.00%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (128.90%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (29.80%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.02)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (17.15x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹196.30 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
Premium Valuation Risk (P/E: 41.25x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Bliss GVS Pharma Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Bliss GVS Pharma Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Bliss GVS Pharma LtdBliss GVS Pharm...Selected✓ BLISSGVS • 506197 | 52.8/100 | ₹465.65₹466 | ₹5437.81₹5437.81 | 41.25Average 41.3 Average | 11.75%Average 11.75% Average | 16.93%Good 16.93% Good | 0.02Excellent 0.0 Excellent | 13.98%Good 13.98% Good | 9.94%Good 9.94% Good | 0.29% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Bliss GVS Pharma Ltd PE Ratio History
Historical price-to-earnings ratio for BLISSGVS — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹7.95 | ₹163.39 | 20.6x |
| FY 2024 | ₹7.11 | ₹164.71 | 23.2x |
| FY 2023 | ₹6.72 | ₹124.65 | 18.5x |
| FY 2022 | ₹1.43 | ₹72.40 | 50.6x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Bliss GVS Pharma Ltd Dividend History
Annual cash dividends paid by BLISSGVS — dividend yield 0.29%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹5.45 Cr |
| FY 2024 | ₹5.39 Cr |
| FY 2023 | ₹5.44 Cr |
| FY 2022 | ₹5.33 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Bliss GVS Pharma Ltd Quarterly Performance
Latest quarterly metrics for BLISSGVS — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
29.80%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
128.90%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
9.94%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
13.98%
Compounded annual net profit growth over 5 years
Bliss GVS Pharma Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for BLISSGVS — calculated from daily price history
Selling pressure is heavy — potential reversal zone.
Technical indicators are for educational purposes only. Not investment advice.
Bliss GVS Pharma Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Bliss GVS Pharma Ltd (BLISSGVS) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Bliss GVS Pharma Ltd
About BLISSGVS (Bliss GVS Pharma Ltd)
Bliss GVS Pharma Ltd is a dynamic pharmaceutical entity with a global footprint, dedicated to the innovation and distribution of essential healthcare solutions. The company's core ...focus lies in crafting a diverse portfolio of pharmaceutical formulations, meticulously designed to address a wide spectrum of medical needs. Through rigorous research and development, Bliss GVS Pharma strives to enhance the efficacy and accessibility of its products, ensuring they meet the highest international quality standards. The company's commitment to patient well-being is evident in its unwavering pursuit of pharmaceutical excellence, consistently pushing boundaries to develop advanced and reliable healthcare solutions. The company's manufacturing prowess encompasses a wide array of dosage forms, reflecting its comprehensive approach to pharmaceutical production. From meticulously crafted tablets and capsules to specialized formulations like creams, ointments, and injectables, Bliss GVS Pharma demonstrates versatility in meeting diverse therapeutic demands. The company leverages state-of-the-art facilities and adheres to stringent manufacturing practices to ensure the consistency and integrity of its products. This dedication to quality extends beyond production, encompassing rigorous testing and quality control measures at every stage of the manufacturing process. Bliss GVS Pharma's commitment to global health extends beyond its manufacturing capabilities. The company actively cultivates strategic partnerships and distribution networks to ensure its products reach those who need them most. With a strong presence in both domestic and international markets, Bliss GVS Pharma plays a vital role in providing accessible and affordable healthcare solutions to communities worldwide. The company's dedication to ethical business practices and social responsibility further solidifies its position as a trusted and reliable pharmaceutical partner, committed to improving lives through innovation and accessibility.
Company Details
Key Leadership
Corporate Events
BLISSGVS Share Price: Frequently Asked Questions
What is the current share price of Bliss GVS Pharma Ltd?
Bliss GVS Pharma Ltd (BLISSGVS) trades at ₹465.65 on NSE and BSE. Market cap ₹5.44K (Cr). Educational data only.
What is the P/E ratio of Bliss GVS Pharma Ltd?
Bliss GVS Pharma Ltd has a P/E of 41.25x vs industry average 34.89x.
What is the Bull Run score for Bliss GVS Pharma Ltd?
Bliss GVS Pharma Ltd has a Bull Run score of 52.8/100 based on 25+ financial parameters.
Does Bliss GVS Pharma Ltd pay dividends?
Bliss GVS Pharma Ltd has a dividend yield of 0.29%. Past dividends don't guarantee future payments.
What is the ROE of Bliss GVS Pharma Ltd?
Bliss GVS Pharma Ltd has ROE of 11.75%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Bliss GVS Pharma Ltd?
Bliss GVS Pharma Ltd has debt-to-equity of 0.02.
Is Bliss GVS Pharma Ltd a good investment?
Bull Run gives Bliss GVS Pharma Ltd a score of 52.8/100. This is not investment advice — consult a SEBI-registered advisor.